Galectin Therapeutics Inc. (Nasdaq: GALT) reported positive results for a Phase 1 trial of GR-MD-02 on fibrosis lifting the stock price 74 cents to close at $3.97.
Positive study results for Galectin
January 07, 2015 at 06:18 AM EST
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|